参考文献/References:
[1] Xu X, Li Z, Gao W.Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside[J].Biomarkers,2011,16(6):466-475.
[2] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[3] Xu J, Kjmball TR, Lorenz JN, et al.GDF-l5/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation[J].Circ Res,2006,98(3):342-350.
[4] Kempf T,Wollert KC.Growth differentiation factor 15:a new biomarker in cardiovascular disease[J].Herz,2009,34(8):594-599.
[5] Putko BN,Yogasundaram H,Oudit GY. The harbinger of mortality in heart failure with preserved ejection fraction: do GDF-15 levels reflect tandem, deterministic effects of fibrosis and inflammation?[J].Can J Cardiol,2014,30(3):264-266.
[6] Przybyowski P, Wasilewski G, Bachorzewska-Gajewska H,et al. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure[J].Transplant Proc,2014,46(8):2852-2855.
[7] Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update[J].Curr Heart Fail Rep,2012,9(4):337-345.
[8] Kempf T, Horn-Wichmann R, Brabant G,et al.Circulating concentrations of growth differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay[J].Clin Chem,2007,53(2):284-291.
[9] Wang F, Guo Y, Yu H,et al. Growth differentiation factor 15 in different stages of heart failure:potential screening implications[J].Biomarkers,2010,15(8):671-676.
[10] Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure[J].J Am Coll Cardiol,2007,50(11):1054-1060.
[11] Meta-analysis Global Group in Chronic Heart Failure(MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction:an individual patient data meta-analysis[J]. Eur Heart J,2012,33(14):1750-1757.
[12] Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction[J]. Eur J Heart Fail,2010,12(12):1309-1316.
[13] Dinh W, Füth R,Lankisch M, et al. Growth-differentiation factor-15:a novel biomarker in patients with diastolic dysfunction?[J]. Arq Bras Cardiol,2011,97(1):65-75.
[14] Meluzin J, Hude P, Leinveber P, et al. High prevalence of exercise-induced heart failure with normal ejection fraction in post-heart transplant patients[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2014,158(2):295-302.
[15] Meluzín J, Tomandl J. Can biomarkers help to diagnose early heart failure with preserved ejection fraction?[J].Dis Markers,2015,2015:426045.
[16] Baessler A, Strack C, Rousseva E, et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity[J].Eur J Heart Fail, 2012,14(11):1240-1248.
[17] Pouleur AC. Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction?[J].Clin Chim Acta,2015,443:9-16.
[18] Dirk J, Ijsbrand T, Sjoukje I, et al. Incremental prognostic power of novel biomarkers(growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T)in patients with advanced chronic heart failure[J].Am J Cardiol,2013,112(6):831-837.
[19] Izumiya Y,Hanatani S,Kimura Y,et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction[J].Can J Cardiol,2014,30(3):338-344.
[20] Eggers KM, Kempf T, Wallentin L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals[J].Clin Chem,2013,59(7):1091-1098.
[21] Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth differentiation factor-15 in heart failure:relation to disease severity and prognosis in the Valsartan Heart Failure trial[J]. Circulation,2010,122(14):1387-1395.
[22] Ahmad T, Wang T,O'Brien EC, et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury[J].JACC Heart Fail,2015,3(1):30-39.
[23] Peeters JM,Sanders-van Wijk S,Bektas S,et al. Biomarkers in outpatient heart failure management; Are they correlated to and do they influence clinical judgment?[J].Neth Heart J,2014,22(3):115-121.
[24] Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome:observations from PROVE IT-TIMI 22[J].Arterioscler Thromb Vasc Biol,2011,31(1):203-210.
相似文献/References:
[1]赵诚,综述,朱丹,等.甲状旁腺功能减退与心脏损害[J].心血管病学进展,2016,(2):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
ZHAO Cheng,ZHU Dan.Hypoparathyroid and Cardiac Damage[J].Advances in Cardiovascular Diseases,2016,(6):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
[2]王振,综述,惠杰,等.迷走神经刺激与心力衰竭[J].心血管病学进展,2016,(2):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
WANG Zhen,HUI Jie.Vagus Nerve Stimulation and Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
[3]陈焕,综述,邓平,等.S100A1蛋白基因治疗心力衰竭的研究进展[J].心血管病学进展,2016,(3):302.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.023]
CHEN Huan,DENG Ping.Research Progress in S100A1 Gene Therapy for Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):302.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.023]
[4]唐毅,柳志红,黄智伟,等.运动振荡呼吸在心力衰竭中的应用[J].心血管病学进展,2015,(5):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
TANG Yi,LIU Zhihong,HUANG Zhiwei,et al.Application of Exercise Oscillatory Ventilation in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
[5]梅宝菲,孔一慧,李为民.睡眠障碍与心血管疾病研究新进展[J].心血管病学进展,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
MEI Baofei,KONG Yihui,LI Weimin.Relationship Between Somnipathy and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(6):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
[6]唐光能,洪炳哲.Junctate蛋白在心力衰竭中的研究进展[J].心血管病学进展,2015,(5):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
TANG Guangneng,HONG Bingzhe.Research Development of Junctate Protein in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
[7]姜琳,袁晋青.缺血性心肌病的血运重建治疗[J].心血管病学进展,2015,(6):677.[doi:10.3969/j.issn.1004-3934.2015.06.006]
JIANG Lin,YUAN Jinqing.Revascularization in Ischemic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(6):677.[doi:10.3969/j.issn.1004-3934.2015.06.006]
[8]秦莉 张艺文 杨晓倩 王燕凤 汪汉.系统性红斑狼疮合并心力衰竭的发病机制及病因[J].心血管病学进展,2020,(4):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]
QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.The Pathogenesis and Etiology of Heart Failure in Systemic lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(6):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]